Innovative Industrial Properties Class Action Lawsuit (IIPR)

Jan 20, 2025 | Investigations

Class Action Lawsuit Filed Against IIPR: Key Allegations

On January 17, 2025, a class action lawsuit was filed against Innovative Industrial Properties, Inc. (“IIPR” or the “Company”) (NYSE: IIPR) on behalf of investors who acquired IIPR securities between February 27, 2024, and December 19, 2024 (the “Class Period”).

If you purchased or otherwise acquired IIPR shares during the Class Period, click here to send us a message for more information about the IIPR class action lawsuit.

How to Provide Information

To share details about your financial losses or to be contacted by a member of our team, please complete our brief securities questionnaire. Alternatively, you can reach out to Michael Yarnoff, Esq., for a no-obligation evaluation of potential legal claims:

Class Action Lawsuit Allegations

According to the complaint, the defendants allegedly made materially false and misleading statements about the Company’s business, operations, and financial prospects during the Class Period. Specifically, the complaint alleges the following:

  1. IIPR was experiencing significant declines in rent and property-management fees associated with certain customer leases.
  2. These declines would likely impair the Company’s ability to maintain funds from operations (FFO) and revenue growth.
  3. Consequently, IIPR’s leasing operations were less profitable than the Company had represented to investors.
  4. As a result, IIPR’s public statements were materially false and misleading throughout the Class Period.

To review the complaint, click IIPR class action complaint.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C., is a multidisciplinary, plaintiff-side class action law firm committed to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead or Co-Lead Counsel in cases recovering over $10 billion on behalf of institutional and individual investors.

 

 

 

Please submit this form if you have incurred financial losses.

By clicking and submitting this form, you acknowledge that this does not establish an attorney-client relationship between you and Kehoe Law Firm, P.C. (“KLF” or “Firm”), and that the submission or receipt of information to the Firm or one of its attorneys via this form, website, email or telephone does not create an attorney-client relationship.  All submissions are confidential, and there is no cost or obligation incurred by providing your information to Kehoe Law Firm, P.C. By submitting this form, you authorize KLF to contact you regarding this or future cases. 

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Walgreens Securities Investigation – WBA

Jan 18, 2025 | Investigations

Kehoe Law Firm, P.C. is investigating securities class action claims on behalf of shareholders of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA).

WALGREENS INVESTORS WITH FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. FOR A FREE, NO OBLIGATION EVALUATION OF POTENTIAL LEGAL CLAIMS.

Investors of Walgreens should be aware that the U.S. Department of Justice (“DOJ”) has filed a civil complaint in federal court alleging that Walgreens Boots Alliance, Walgreen Co. and various subsidiaries dispensed millions of unlawful prescriptions in violation of the Controlled Substances Act (“CSA”) and then sought reimbursement for many of these prescriptions from various federal health care programs in violation the False Claims Act (“FCA”).

According to the complaint, “. . . from approximately August 2012 through the present, Walgreens knowingly filled millions of prescriptions for controlled substances that lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice. Among the millions of unlawful prescriptions that Walgreens allegedly filled were prescriptions for dangerous and excessive quantities of opioids, prescriptions for early refills of opioids and prescriptions for the especially dangerous and abused combination of drugs known as the ‘trinity,’ which is made up of an opioid, a benzodiazepine and a muscle relaxant.”

On this news, the stock price of Walgreens dropped more than 5% after the stock market closed on January 17, 2025.

WALGREENS SHAREHOLDERS INTERESTED IN LEARNING MORE ABOUT THE SECURITIES CLASS ACTION INVESTIGATION CAN ALSO EMAIL [email protected] OR CONTACT EITHER JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected].

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Comerica Inc. – Investigation Regarding Comerica’s Service of Direct Express Cardholders – NYSE: CMA

Jan 15, 2025 | Investigations

Kehoe Law Firm, P.C. is invesigating whether certain executive officers or board members of Comerica Inc. (“Comerica”) (NYSE: CMA) failed to manage Comerica in an acceptable manner, in breach of their fiduciary duties to Comerica, and whether Comerica and its shareholders were harmed as a result.

CURRENT INVESTORS OF COMERICA STOCK ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. FOR A FREE EVALUATION OF POTENTIAL LEGAL CLAIMS.

CFPB v. Comerica Bank

On December 6, 2024, the Consumer Financial Protection Bureau (“CFPB”) sued Comerica Bank, a subsidiary of publicly traded Comerica Inc., for systematically failing its 3.4 million Direct Express cardholders – primarily unbanked Americans receiving federal benefits.

Comerica Bank, according to the CFPB, deliberately disconnected 24 million customer service calls, impeding cardholders from exercising their rights under the law, charged illegal ATM fees to over 1 million cardholders, and mishandled fraud complaints while providing federal benefits through the Direct Express prepaid debit card program.

Key CFPB Lawsuit Allegations About How Comerica Harmed its Customers:

  • Deliberately disconnecting customer service calls: Comerica’s vendors intentionally dropped more than 24 million calls from customers before they could reach a representative. Customers whose calls were not dropped were routinely forced to endure excessively long wait times—often in excess of several hours—to speak with a representative to get help with unauthorized transactions, charge disputes, and lost or stolen cards.
  • Charging consumers illegal ATM fees: Over one million Direct Express cardholders were charged ATM fees to access their government benefits in situations where they were legally entitled to free withdrawals.
  • Misleading fraud victims: When consumers contacted Comerica alleging they had been fraudulently enrolled into the Direct Express program, the bank’s vendors frequently advised the consumers that “no error occurred” where the bank had determined that there was, in fact, enrollment fraud.
  • Imposing illegal terms of service on consumers seeking to stop payments: Comerica led its consumers to agree to waive their consumer protections by requiring cardholders to contact and request merchants to stop pre-authorized payment transfers from their account in situations where the law in fact required the bank to stop the transfers itself.
  • Failing to investigate account problems: Under federal law, when a customer notifies a bank about an incorrect or potentially fraudulent charge on their account, the bank must take steps to investigate the error within a specified time period. The CFPB’s investigation found that Comerica failed to meet this requirement more than 20,000 times. And when they did investigate, they frequently provided vague and confusing findings or blew off customers altogether.
  • Forcing consumers to close accounts, which often resulted in additional fees: The bank’s vendors required thousands of cardholders to close their accounts to stop a preauthorized payment, resulting in consumers incurring additional fees to expedite receipt of their new debit cards to regain access to their government benefits.

Read the CFPB complaint by clicking CFPB v. Comerica Bank.

COMERICA SHAREHOLDERS ALSO CAN CLICK HERE, EMAIL [email protected], OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected] TO LEARN MORE ABOUT THE COMERICA BREACH OF FIDUCIARY DUTIES INVESTIGATION.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Signet Jewelers Securities Investigation (SIG)

Jan 14, 2025 | Investigations

Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of Signet Jewelers Ltd. (“Signet” or “Signet Jewelers”) (NYSE: SIG).

INVESTORS OF SIGNET STOCK WITH FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. FOR A FREE EVALUATION OF POTENTIAL LEGAL CLAIMS RELATED TO SIGNET JEWELER’S STOCK DROP.

Investing.com reported that “[t]he world’s largest retailer of diamond jewelry reported weaker holiday sales, with same-store sales . . . for the ten weeks ending January 11, 2025, declining by approximately 2%.”

On this news, Signet Jeweler’s stock was down more than 21% during intraday trading on January 14, 2025.

Investors of Signet stock should be aware that the recent news contrasts with the positive statements made by Signet on 12/5/2024. Among other things, Signet stated that it “. . . believes it is positioned to deliver a positive holiday performance this year, driven by our comprehensive go-to-market strategy which will lean into our strengths in fashion newness and services, as well as capitalize on the moderate increase in engagement units expected in the fourth quarter.”

INVESTORS OF SIGNET STOCK WITH FINANCIAL LOSSES INTERESTED IN LEARNING MORE ABOUT THE SECURITIES CLASS ACTION INVESTIGATION ALSO CAN EMAIL [email protected], OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected].

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

TransMedics Group Securities Investigation (TMDX)

Jan 10, 2025 | Investigations

Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) stock after the Company’s stock price dropped significantly during intraday trading today.

INVESTORS OF TRANSMEDICS STOCK WITH FINANCIAL LOSSES MAY HAVE LEGAL OPTIONS AND ARE ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C. FOR A FREE EVALUATION OF POTENTIAL SECURITIES CLAIMS RELATED TO TMDX’S STOCK DROP.

The Company’s stock decline follows the release of a critical report by Scorpion Capital, accusing TransMedics of unethical business practices, including extortion, racketeering, and organ trafficking under the guise of a medical device company.

Key Allegations in the Scorpion Capital Report:

  • “Mafia-style” extortion, racketeering, and organ trafficking schemes
  • Kickbacks and billing fraud
  • Unreported device failures and off-label misuse of the Organ Care System

INVESTORS OF TRANSMEDICS STOCK WITH FINANCIAL LOSSES INTERESTED IN LEARNING MORE ABOUT THE CLASS ACTION INVESTIGATION ALSO CAN CLICK HERE, EMAIL [email protected], OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected].

NeueHealth Stock Alert: Merger Investigation on Behalf of Investors of NEUE Stock

Jan 3, 2025 | Investigations

NeueHealth Stock – Is the Proposed Acquisition of NeueHealth By An Affiliate of Its Controlling Shareholder Fair to NEUE Shareholders? –  Kehoe Law Firm, P.C. Investigating

Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of NeueHealth, Inc. (“NeueHealth”) (NYSE: NEUE) regarding the adequacy and fairness of the proposed acquisition by NeueHealth’s controlling shareholder, New Enterprise Associates (“NEA”).

Under the terms of the proposed all-cash transaction, NEA’s affiliate would acquire NeueHealth for $7.33 per share. NEA already owns 53.8% of NeueHealth, raising significant concerns about the fairness and independence of the process undertaken by NeueHealth’s Board of Directors.

INVESTORS OF NEUEHEALTH STOCK CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

KEY INVESTIGATIVE CONCERNS:

Inadequate Deal Protections:  Although NeueHealth’s Board formed a special committee, it does not appear to have implemented customary safeguards, such as requiring a majority of the minority vote to approve the transaction.

Below-Market Valuation: The offer price of $7.33 per share is substantially below NeueHealth’s 52-week average price of $16.59 and its 52-week high of $31.00, suggesting an undervaluation that does not reflect NeueHealth’s true potential.

Conflict of Interest: Was the transaction the result of a flawed process driven by a conflicted board, heavily influenced by the controlling shareholder?

CURRENT SHAREHOLDERS OF NEUEHEALTH STOCK INTERESTED IN SEEKING ADDITIONAL INFORMATION ABOUT THE MERGER INVESTIGATION AND POTENTIAL LEGAL CLAIMS CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected].